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Abstract
Background: Genetic variation is an important determinant of RNA transcription and splicing, which in turn
contributes to variation in human traits, including cardiovascular diseases.
Results: Here we report the first in-depth survey of heart transcriptome variation using RNA-sequencing in 97
patients with dilated cardiomyopathy and 108 non-diseased controls. We reveal extensive differences of gene
expression and splicing between dilated cardiomyopathy patients and controls, affecting known as well as novel
dilated cardiomyopathy genes. Moreover, we show a widespread effect of genetic variation on the regulation of
transcription, isoform usage, and allele-specific expression. Systematic annotation of genome-wide association SNPs
identifies 60 functional candidate genes for heart phenotypes, representing 20% of all published heart genome-wide
association loci. Focusing on the dilated cardiomyopathy phenotype we found that eQTL variants are also enriched for
dilated cardiomyopathy genome-wide association signals in two independent cohorts.
Conclusions: RNA transcription, splicing, and allele-specific expression are each important determinants of the dilated
cardiomyopathy phenotype and are controlled by genetic factors. Our results represent a powerful resource for the
field of cardiovascular genetics.
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Background
In recent years genome-wide association studies (GWAS)
have identified thousands of disease-associated genetic
variants. However, the underlying disease-causing molecu-
lar mechanisms have remained largely elusive because
these variants are located predominantly in the noncoding
part of the genome [1]. Many variants have been shown to
coincide with regulatory elements residing in the noncod-
ing part of the genome [2, 3]. Large scale analysis of the
genetics of intermediate molecular phenotypes, such as
gene and transcript expression levels [4–7] and markers of
chromatin states [8–11], can be used to identify regulatory
variants and to characterize their role in disease [2, 8, 9,
12]. Regulatory elements, and therefore also the effects of
variants on the functioning of these elements, can be
highly tissue-specific; hence, it is important to investigate
the tissue relevant for the disease [2, 3, 7, 13].
Here we characterized global gene expression in the
left ventricular myocardium of human hearts to study
dilated cardiomyopathy (DCM), a common cause of heart
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failure ultimately leading to premature death [14].
Myocardial ischemia as well as toxic, metabolic, and
immunologic factors [15] can lead to the DCM phenotype.
Moreover, genetic susceptibility plays an important role,
with at least 23% of DCM cases being familial [16], and
more than 50 genes linked to inherited DCM [15]. The
most common genetic cause of DCM are truncating
mutations in the gene encoding Titin (TTN), a giant
sarcomeric protein that spans from the A-band to the
Z-disc of the sarcomere [17, 18]. These mutations either
introduce a premature stop codon [19, 20] or affect alter-
native splicing of the >100-kb-long messenger RNA [21].
Titin transcript processing is controlled by the DCM-
associated splicing factor RBM20 [21–24], which targets a
number of additional DCM-associated genes. The myosin
heavy chain locus represents a well characterized example
of transcriptional regulation of both protein-coding [25]
and noncoding DCM-associated genes [26].
In this study we surveyed the cardiac transcriptome of
left ventricular tissue of DCM patients and non-diseased
donors. These datasets were used to characterize the im-
pact of regulatory variation on gene expression and spli-
cing in the heart, and its relation to the biology of DCM.
We analyzed the differences in expression levels between
diseased and non-diseased cardiac tissue, identifying 228
differentially expressed genes. Furthermore, we identified
regulatory variants impacting gene and exon expression
levels. An overlay of our data with published genome-
wide association loci for DCM showed that the identi-
fied regulatory variants are enriched for SNPs tagging
loci associated with DCM risk. Extending our analysis to
GWA loci related to heart physiology in general, we
were able to identify candidate genes for about 20% of
all reported loci.
Results
Gene expression differences between DCM and donor
samples
We generated a detailed inventory of the heart tran-
scriptome by deep RNA sequencing of heart samples of
97 patients with DCM and 108 non-diseased donors.
Selection of the samples and the two study populations
are summarized in Additional file 1: Tables S1 and S2.
Additional clinical information of the DCM patients is
given in Additional file 1: Table S3. On average we gen-
erated 168 million mapped paired-end reads per sample
(Additional file 1: Tables S4 and S5), providing sufficient
depth for detailed characterization of gene expression and
alternative splicing. We have quantified gene expression of
57,820 annotated genes (Gencode v19), including protein-
coding genes, antisense transcripts and long noncoding
RNAs (lncRNAs).
To assess the quality of our data, we first investigated
genes with strong association to DCM described in the
literature. We investigated gene expression differences
between DCM and donor samples for the well-known
DCM-related myosin heavy chain genes MYH6 and
MYH7. We confirmed that the fraction of the adultMYH6
transcripts among all myosin heavy chain RNAs is, on
average, around 10% in donors and virtually absent in the
DCM patients [25] (Additional file 1: Figure S1). Principal
component analysis shows that cases and controls are sep-
arated along the direction of largest variance (Additional
file 1: Figure S2).
We performed a systematic analysis of differential
gene expression between DCM cases and non-diseased
controls and identified 228 protein-coding genes and 53
noncoding RNAs with significant expression differences
and fold changes of at least 20% (Additional files 2 and
3). The top 20 most up- and down-regulated genes are
shown in Table 1. Of these, more than half (11/20) have
been associated with cardiomyopathy prior to this study
while the two most upregulated genes, NPPA and NPPB,
are well established markers of heart failure [27–30].
The latter result confirms the validity of the comparison of
relative expression between DCM cases and non-diseased
donors. Differentially expressed genes were enriched for
Gene Ontology (GO) terms such as structural con-
stituent of muscle (P = 4.59E-04), calcium ion binding
(P= 7.06e-04), regulation of heart contraction (P= 2.56e-07),
and cardiac tissue development (P = 8.77e-05). Among
those genes are eight well known DCM-associated genes
(Additional file 1: Table S6, reproduced from [20]), which
is significantly more than expected by chance (odds ratio
(OR) = 7.9, P = 2.09e-05).These include RBM20, LAMA2,
and TBX20, which were all upregulated in DCM. Differen-
tial expression of TBX20, an important cardiac transcrip-
tion factor, is expected to cause expression changes of
its target genes. We annotated orthologous human tar-
gets of TBX20 using previously published mouse ChIP-
seq data [31] and indeed identified 41 differentially
expressed TBX20 target genes, which are mostly upreg-
ulated (OR = 3.3, P = 1.0e-9, Fisher’s exact test (FET);
Fig. 1).
Splicing differences between DCM and donor samples
Alternative splicing is hypothesized to play an important
role in the etiology of DCM [21, 24, 32] and other car-
diovascular diseases. Here we characterized splicing on
the exon level [33–35]. In order to find the differences
in exon usage between DCM patients and donors, we
used the ‘percentage spliced in’ (PSI) metric that makes
use of reads covering the exons as well as the exon–exon
junctions. We identified 1212 exons that were signifi-
cantly different between DCM patients and donors (false
discovery rate (FDR) <0.05, ΔPSI >0.1; Additional file 4)
corresponding to 899 unique genes. These genes included
11 well known DCM candidate genes (LDB3, LAMA4,
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Table 1 Differentially expressed genes with greatest absolute log fold changes
P value Adjusted
P value
Log
fold
change
DCM
associated
TBX20
target
CMP
associated
Comments
Gene symbol Description
NPPA Natriuretic peptide A 5.61E-09 2.38E-08 0.58 Yes No Yes Natriuretic factor A and B are used
as markers of heart failure progression.
Natriuretic factor implicated in
development and marker of heart failure,
also target of T-box factors [27–30]
NPPB Natriuretic peptide B 1.79E-06 5.57E-06 0.57 Yes Yes Yes See NPPA
TBX20 T-box 20 2.87E-25 3.01E-23 0.49 Yes No Yes TBOX20 has been associated with the
pathophysiology of DCM in both
animal models and human tissue [82]
Furthermore, mutations in TBX20 are
associated with familial DCM [83, 84]
MYLK3 Myosin light chain kinase 3 1.07E-21 3.15E-20 0.42 Yes No Yes Associated with stress adaptation and
progression to heart failure [85–87]
CLIC5 Chloride intracellular
channel 5
2.88E-26 5.40E-24 0.38 No No No CLIC5 is a member of the family of
intracellular Ca2+ channels, associated
with the actin cytoskeletal system.
Thus far no link with DCM has been
described
TRIM44 Tripartite motif containing 44 4.51E-28 3.73E-25 0.38 No No No Thus far no link with DCM has been
described
MAVS Mitochondrial antiviral
signaling protein
5.05E-25 4.67E-23 0.36 No No No Thus far no link with DCM has been
described
NPR3 Natriuretic peptide
receptor 3
3.68E-23 1.68E-21 0.36 No No Yes NPR3 is the receptor for natriuretic
peptides in the heart; it is therefore a
candidate for studies into the modulation
of NPs in (DCM-related) heart failure [88].
SMCR8 Smith-Magenis syndrome
chromosome region,
candidate 8
3.66E-28 3.46E-25 0.34 No No No Thus far no link with DCM or the heart
has been described
JAK2 Janus kinase 2 2.45E-22 8.67E-21 0.32 No Yes Yes JAK2/STAT3 signaling is, amongst other
processes, involved myocardial infarction/
reperfusion injury, and hypertrophic
remodeling in mice. Thus far no direct
link with DCM has been described [89]
TUBA3D Tubulin alpha 3d 1.66E-08 6.63E-08 -0.26 No No No Thus far no link with DCM or the heart
has been described
GADD45B Growth arrest and DNA
damage inducible beta
1.43E-08 5.75E-08 -0.27 No No Yes Changes in expression of GADD45B are
observed in MI induced HF [90]
DLK1 Delta like non-canonical
Notch ligand 1
9.83E-09 4.03E-08 -0.28 No No No Thus far no link with DCM or the heart
has been described
TUBA3E Tubulin alpha 3e 1.17E-10 6.04E-10 -0.30 No No No Thus far no link with DCM or the heart
has been described
GADD45G Growth arrest and DNA
damage inducible gamma
2.87E-11 1.58E-10 -0.31 No Yes Yes Gadd45g overexpression promotes heart
failure and cardiac remodeling after MI;
while knockout mice are resistant to
heart failure [91]
RASD1 Ras related dexamethasone
induced 1
3.32E-07 1.14E-06 -0.32 No No No RASD1 may be involved in the cardiac
release of ANF and BNP upon atrial
volume overload in rats [92]. The RASD1
locus is associated with coronary artery
disease in human GWAS [93]
MYL7 Myosin light chain 7 8.29E-10 3.89E-09 -0.33 No No No Thus far no link with DCM has been
described
FOS Fos proto-oncogene, AP-1
transcription factor subunit
5.58E-08 2.09E-07 -0.33 No Yes Yes c-FOS is used as a marker of heart
failure [94]
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DTNA, TMPO, TTN, TAZ, FLT1, DSP, SYNE1, EYA4, and
DMD), which is significantly more than expected by
chance (OR = 3.8, FET P = 4.4e-04). Differentially spliced
genes were enriched for the GO terms MAPK binding
(P = 6.77E-05), cytoskeleton organization (P = 1.07E-07),
actin filament organization (P = 2.12E-05), Z disc (P =
1.10E-03), and I band (P = 4.40E-03). We have previously
shown that the splicing factor RBM20 is implicated in
DCM [21] and directly regulates splicing of TTN, LDB3,
and other DCM candidate genes [21, 24]. In this data set
the known RBM20 targets TTN, CAMK2D, RTN4, and
paralogs PDLIM5 and SORBS2 of the known targets
Pdlim3 and Sorbs1 were differentially spliced. DCM hearts
expressed longer TTN isoforms, which is known to cause
disease in RBM20-mediated cardiomyopathy [24].
Genetic effects on the transcriptome
We characterized the impact of naturally occurring gen-
etic variation on the regulation of gene expression and
splicing. To this end genotype data were obtained from
SNP arrays for all samples. After stringent quality control
(see Methods: Additional file 1: Table S7), we imputed var-
iants from the 1000 Genomes project [36]. Imputation
quality was assessed using genotype calls obtained from
the RNA-seq reads and was high for variants with minor
allele frequency (MAF) >10% (Additional file 1: Figure S3).
Table 1 Differentially expressed genes with greatest absolute log fold changes (Continued)
MYH6 Myosin heavy chain 6 2.12E-09 9.50E-09 -0.34 Yes Yes Yes MYH6 mutations are associated with
familial DCM [95]
DHRS7C Dehydrogenase/
reductase 7C
3.31E-09 1.45E-08 -0.39 No No Yes Decrease of DHRS7C is observed in
mouse models of heart failure and
in human cardiac tissue of heart
failure patients [96, 97]
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Fig. 1 DCM-associated expression of TBX20 targets. Differential expression of human orthologs of TBX20 targets in the mouse heart is shown as a
heatmap of gene expression values standardized to mean zero and standard deviation one
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We therefore selected only variants with MAF >10%,
resulting in 1,851,329 high confidence imputed variants
for quantitative trait locus (QTL) analysis.
Cis expression QTL (eQTL) analysis of protein-coding
and long noncoding transcripts uncovered widespread
genetic effects on gene expression levels. In concordance
with earlier studies in cell lines [4–6] and other tissues
[7] as well as previous studies in the heart [7], we found
eQTL for 17% of protein-coding genes and for 18% of
noncoding transcripts (Table 2). In total we identified
188,821 SNPs affecting the transcript levels of 5074
unique genes in the combined expression data of controls
and DCM samples adjusted for sex, age, disease status,
and additional covariates. We systematically compared
our results to eQTL from left-ventricular tissue of the
GTEx project [7] (see also Additional file 1: Supplemental
notes for a concise summary of all GTEx comparisons),
which comprises 190 samples in version 6. For the com-
parison on the SNP level, we selected the most significant
marker for each gene with cis eQTL in our study (nominal
P < 1e-5). Among the top SNPs, 82% were also analyzed in
the GTEx study. Of these, 97% had concordant allelic ef-
fects (Additional file 1: Figure S4), although only 40%
reached the significance threshold in GTEx. The larger
number of eQTL detected in our study is most likely due
to reduced statistical power caused by a slightly smaller
sample size or the use of post-mortem tissues in the GTEx
project. Using Storey’s q-value method [37], we estimated
that 93% of eQTL are actually shared. Conversely, we have
analyzed 18% of the top GTEx SNPs for genes with cis
eQTL, of which 72% were significant in our study, 97%
had concordant allelic effects, and 92% were estimated to
be shared. Together these estimates suggest that our study
is well replicated by the GTEx study.
As cis-regulatory variation is dependent on the con-
text, such as the expression or activity of trans-factors
(i.e., transcription factors), which might be dramatically
altered in the hearts of DCM patients, we studied the
presence of DCM/donor specific cis eQTL (Additional
file 5). Using nested linear models we found 100 DCM-
specific and 128 eQTL that were specific for donors.
Only three of the specific eQTL SNPs showed evidence of
differences in allele frequencies between groups (Armitage
trend test, P < 0.01). Given the presence of DCM and
donor-specific eQTL, we repeated the comparison of
eQTL results from each population separately with GTEx
(Additional file 1: Figures S5 and S6 and Table S8). We
also compared the 100 DCM-specific eQTL with GTEx
results and found that only 9.3% were also significant
in this non-diseased population.
We looked for examples of genes with specific cis
eQTL that have previously been discussed in the context
of DCM in the literature. A DCM-specific eQTL was
JUND, which is specifically expressed during heart de-
velopment [38]. Higher levels of JUND expression are
observed in DCM patients. Interestingly, DCM patients
carrying the A allele of rs11085247 show even higher
expression levels (Fig. 2a). In donors TXNDRD2 had an
eQTL at rs11704083, which was not present in DCM
samples (Fig. 2b). Mutations in TXNDRD2 have been
associated with DCM [39] and heart-specific loss of
TXNDRB2 expression leads to a DCM-like phenotype
in mice [40].
Genetic effects on splicing
Since alternative splicing is hypothesized to play an im-
portant role in the etiology of DCM [21, 24, 32] and
other cardiovascular diseases, we set out to identify spli-
cing QTL (sQTL) using an exon-based model similar to
DEXSeq [33]. In addition we also used a gene level test
that associates changes of relative transcript isoform
abundance with genotypes [41] to identify transcript
ratio QTL (trQTL). We found evidence for extensive
genetic regulation of splicing, with 11.8% of tested exons
and 14.6% of tested genes showing sQTL and trQTL, re-
spectively (Table 2). In both approaches we ruled out con-
founding by RBM20 expression by estimating that the
upper limit for the fraction of significant trans associations
of sQTL SNPs to RBM20 was below 1%. We compared
the exon-based (sQTL) and the transcript-based (trQTL)
approaches in terms of overlapping genes and overlapping
SNPs with significant QTL. The gene level comparison
showed that 45% of genes with trQTL were also detected
as sQTL and, vice versa, 24% of genes with sQTL were
also detected as trQTL. Similar numbers were obtained
on the SNP level, with 41 and 26%, respectively. Both
comparisons revealed a higher power to detect QTL with
the exon-based approach, which is most probably due
to the uncertainty in transcript isoform quantification.
In comparison to the GTEx study (242 trQTL, ~1.2%
of tested genes), we identified over ten times as many
trQTL. To investigate the possible factors leading to
this increase in detection rate, we matched our data set
to the GTEx data set in terms of read depth, sample
size and size of the cis window (see “Methods”). In this
matched analysis we estimated that 1.5% of genes have
trQTL (Table 3), which is in accordance with GTEx. This
estimate suggests that the increased rate of detection in
Table 2 Summary of QTL results
Type Number
tested
Number of
significant cis QTL
Percentage
significant cis QTL
Exons 48,119 5,702 11.8
Transcript
isoform ratios
19,736 2,874 14.6
Protein-coding 17,323 3,360 19.2
lncRNA 2,887 547 18.5
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our study is attributable to the increased sample size, in-
creased cis window size, as well as sequencing depth,
highlighting the importance of sequencing depth to inves-
tigate post-transcriptional regulation (Table 3).
eQTL and sQTL are overrepresented in known regulatory
regions
We functionally annotated the genetic variants that affect
gene expression and splicing. eQTL and sQTL have previ-
ously been shown to frequently reside in cis regulatory
elements [6, 7, 42, 43]. We have annotated variants with
features based on transcript annotation, position of the
variant relative to its target, and an epigenome annotation
specific for the left ventricle of the heart from the Epige-
nomics Roadmap project [44] based on the ChromHMM
[45] segmentations of histone modification ChIP-seq data.
As described previously [6, 42, 43], we found a strong en-
richment of QTL variants around the transcription start
site (TSS) for eQTL (Additional file 1: Figure S7a) and
around the target exon for sQTL (Additional file 1: Figure
DCM control
3.25
3.50
3.75
4.00
4.25
GG GA AA GG GA AA
rs11085247
E
xp
re
ss
io
n
JUND
DCM control
3.0
3.1
3.2
3.3
3.4
AA AG GG AA AG GG
rs11704083
E
xp
re
ss
io
n
TXNRD2a b
Fig. 2 DCM- and control-specific eQTL. Boxplots show examples of eQTL where the genotype only affects expression levels in a DCM patients or
b controls. Expression levels are shown as log transformed normalized read counts. The x-axis indicates the genotype of the SNP
Table 3 Effect of read depth, sample size, and covariate adjustment on trQTL detection
Cis radius Reads matcheda Samples matchedb Adjusted for covariates Genes tested Genes with trQTLc Percentage with trQTLc
500 kb Yes Yes No 462 19 4.11%
500 kb Yes Yes Yes 457 26 5.69%
500 kb Yes No No 465 43 9.25%
500 kb Yes No Yes 458 58 12.66%
500 kb No No No 19,736 2874 14.56%
500 kb No No Yes 14,586 3588 24.60%
5 kb Yes Yes No 394 6 1.52%
5 kb Yes Yes Yes 377 9 2.39%
5 kb Yes No No 398 32 8.04%
5 kb Yes No Yes 351 33 9.40%
5 kb No No No 16,208 2088 12.88%
5 kb No No Yes 10,304 2469 23.96%
aAnalysis of chromsome 20 matched to 1.7 million reads corresponding to an estimated total read count of 80 million (GTEx median = 82.1 million)
b83 non-diseased samples (GTEx left ventricle, 83)
cFDR <0.05
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S7b). Figure 3 shows that eQTL are enriched in TSSs,
exons, and introns even when adjusting for distance ef-
fects. Moreover, there was also enrichment in more distant
elements such as enhancers, whereas heterochromatin re-
gions were depleted of eQTL. sQTL showed the strongest
enrichment when they were located directly within the
target exon but also the downstream neighboring exon. In
contrast, SNPs in neighboring introns were depleted for
sQTL. In addition to the enrichment within the target
exon, SNPs that were located in exonic splice enhancer
sequences show an enrichment for sQTL, corroborat-
ing the important role of these cis regulatory sequences
for splicing [46]. We also found enrichment of annota-
tions related to transcriptional regulation, such as pro-
moters and DNAse hypersensitivity sites as well as
polycomb-associated regions (Fig. 3).
Genes with allelic imbalance differences are enriched for
DCM-related processes
Allele specific expression (ASE) is an additional mechan-
ism for naturally occurring variation to affect gene expres-
sion. To assess ASE, reference-alternative allele ratios
were determined in the aligned RNA-seq reads for all het-
erozygote sites in each individual, and their deviation from
the expected 50:50 ratio was used as a measure of allelic
imbalance. Only sites passing strict quality criteria were
considered (see “Methods” section) and we observed an
overrepresentation of sites located in the 3′ UTR, likely
caused by increased sequencing depth due to poly(A) se-
lection for the RNA-seq analysis (Additional file 1: Figure
S8). Although this commonly observed technical bias in
RNA-seq analysis leads to variants within the 3′ UTR be-
ing detected with greater coverage and quality, these vari-
ants are used to detect imbalance on the gene level
irrespective of relative location. Using this approach, we
identified 6499 sites with allelic imbalance (Additional file
6) in at least one individual, corresponding to 3307 genes.
Enrichment analysis of these genes revealed enrichments
for significant eQTL effects (OR = 1.10, P < 0.05, FET)
and differential splicing (OR = 1.68, P < 2e-06, FET), in
addition to presence of miRNA binding sites (OR = 1.94,
P < 2.2e-16, FET) (Fig. 4a). Enrichment tests for
localization are not affected by the 3′ UTR bias, as the
background set of all tested variants is also enriched in
the 3′ UTR.
We next looked at consistent effects across multiple
individuals. Out of all imbalanced genes, 1582 showed a
difference larger than 0.10 between alternative and refer-
ence allele frequencies consistently across imbalanced
individuals. The remaining 1725 genes demonstrate lar-
ger inter-individual differences in allelic imbalance,
where at the same site either the alternative or reference
allele was overexpressed in different individuals, leading
to an approximate 50:50 ratio when averaged across
sQTL eQTLa b
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Fig. 3 Functional annotation of QTL variants. Enrichment of sQTL (a) and (b) eQTL in functional categories is shown as estimated odds ratios and
95% confidence intervals of the multiple logistic regression model on the x-axis for each annotation category on the y-axis. Odds ratios greater
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individuals. Allelic imbalance observed for these latter
sites could be the result of parental imprinting, although
overlap with known imprinted genes was only small
(n = 20).
Next, we compared ASE between the DCM cases and
donors. We observed significant differences in the rela-
tive number of imbalanced individuals at 448 shared
sites. Out of all differential ASE sites, 133 showed a dif-
ference between alternative and reference allele ratio
larger than 0.10. These sites are located in 132 unique
genes (Additional file 7), which were significantly
enriched for differential splicing (OR = 2.55, P < 0.05,
FET) and presence of miRNA binding sites (OR = 1.66,
P < 0.05, FET) (Fig. 4b). Next, we assessed the biological
function of the differentially imbalanced genes. One of
the top ten differentially imbalanced genes is FSTL1
(DCM, 24 out of 42 heterozygotes imbalanced; donors,
10 out of 44 heterozygotes imbalanced; alternative/refer-
ence ratio = 40:60; P < 0.05, FET). Apart from showing a
strong difference in imbalance between DCM cases and
donors, FSTL1 is a known cardioprotective gene, acting as
an autocrine/paracrine regulatory factor that antagonizes
myocyte hypertrophic growth and the loss of ventricular
performance in response to pressure overload [47], and
shown to be able to prevent myocardial ischemia/reperfu-
sion injury by inhibiting apoptosis and inflammatory re-
sponse [48]. The only known DCM-related gene that is
differentially imbalanced between DCM cases and donors
is TTN, but sample size for the heterozygous variant used
in the ASE analysis is very low (DCM, 4 out 9 imbalanced;
donors, 12 out of 13 imbalanced; alternative/reference
ratio = 38:62; P < 0.05, FET). Extending on this beyond
differential imbalance, we did not observe any consistent
strong allele-specific expression effects in TTN across all
samples. GO enrichment analysis revealed biological
processes known to be implicated in DCM [20], includ-
ing heart development, actin filament-related processes,
muscle development and mitochondrial processes
(Additional file 1: Table S9). Furthermore, we observed
enrichment for genes involved in cytoskeletal protein
binding, as well as external matrix and laminin binding,
pointing to genes involved in maintaining structural
stability on both the cellular and tissue level. Laminins
are pivotal for the maintenance and survival of tissues
and defects in laminins are known to lead to forms of
muscular dystrophy [49, 50]. Together, these results
suggest that in DCM hearts, overexpression of specific
alleles of genes involved in processes known to play im-
portant roles in establishing the DCM phenotype occurs
partly through differential splicing and partly through
miRNA interference.
sQTL and eQTL are enriched for DCM variants
We analyzed genome-wide association (GWA) data from
two studies that looked for loci involved in DCM in a
German population [51] and a set of European popula-
tions [52]. We investigated whether the transcriptome
altering QTL variants (not specific for DCM or controls)
we have identified are enriched for DCM-GWA associ-
ation signals. Since the GWA studies and eQTL studies
were carried out on different genotyping platforms, we
defined linkage disequilibrium (LD) blocks [53] with Rsq
>0.6 from 1000 Genomes data and tested whether the
distributions of association P values of LD blocks with
and without QTL differ [54]. We found a highly significant
enrichment (Fig. 5; P < 2.2e-16) of small GWA P values
for LD blocks with a sQTL in the German DCM GWAS
(909 cases versus 2120 controls), which was subsequently
a b
Fig. 4 Enrichment for significant eQTLs, miRNA interference, and significant differential splicing in genes with allele-specific expression. Odds
ratios with 95% confidence intervals for enrichment are given. a All genes with allele-specific expression in at least one individual. Significant
enrichment for significant eQTLs, differential splicing, and presence of miRNA binding sites was observed. b All genes with differential allele-specific
expression between DCM and non-diseased controls with alternative/reference allele frequency difference >0.10. Significant enrichment for differential
splicing and presence of miRNA binding sites was observed, with suggestive enrichment for significant eQTLs
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replicated (P < 2.2e-16) in the international DCM GWAS
(1179 cases versus 1108 controls). Similarly, LD blocks
with eQTL were also enriched for small GWA P values in
both GWAS (Fig. 5; P < 2.2e-16). A similar comparison of
LD blocks with ASE variants to the background of all LD
blocks of SNPs tested for ASE also showed significant
shifts in the P value distributions in both GWA studies
(Fig. 5c, d; P = 6.80e-07 and P = 4.20e-08). Focusing on
DCM-specific eQTL, we also observed this shift in the P
value distributions (P < 5.78e-10 in [51] and P < 8.99e-12
in [52]). These results indicate that the genomic regions in
which we have identified these sQTL, eQTL, and ASE
SNPs contain genetic variants regulating splicing and tran-
scription that are important in the development of DCM
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Fig. 5 Enrichment of QTL and ASE variants for DCM GWAs. Cumulative density function (CDF) plots for DCM GWA P values for LD blocks that
have sQTL (red) and eQTL (yellow) compared to the background set of all tested LD blocks using GWA data from a German DCM population (a)
and a European DCM population (b). Similarly, CDF plots of DCM GWA P values for LD blocks with ASE variants (red) are compared to the
background set of all LD blocks with coding SNPs tested for ASE (grey) for a German DCM population (c) and a European DCM population (d)
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in the general population. As such these variants could
point to biologically relevant candidate genes and poly-
morphisms in the context of DCM.
Hence, we were interested in whether these genetic
variants could be used to improve the prediction of
DCM risk. We trained a multilocus genetic risk score
(see “Methods”) using DCM GWA data [51], which
comprises 909 DCM cases and 2120 controls from
Germany. We selected the most predictive variables
from covariates (sex and age), eQTL SNPs, sQTL SNPs,
and the DCM GWA SNP rs9262636. In a tenfold cross
validation we found that the selection based on all can-
didate variables yielded risk scores with the largest area
under the ROC curve (median AUC = 0.70; Additional
file 1: Figure S9). A model based only on the GWA SNP
yielded a median AUC = 0.65 and a model based on age
and sex only resulted in median AUC = 0.63. Overall we
observed a moderate improvement of the risk score
when including eQTL and sQTL, indicating that these
SNP sets encoded relevant information on DCM risk.
eQTL are enriched for heart GWA SNPs
The sQTL and eQTL detected in this study may also
shed light on the underlying biology of other disease/
phenotype-associated variants reported in GWAS for the
heart. We collected SNPs associated with cardiac pheno-
types from the GWA literature [55] and annotated these
with our QTL results (Additional file 8) for genes with
RPKM >1 in >5% of the samples. Overlap between
GWA and eQTL SNPs can be used as functional evidence
to prioritize and implicate candidate genes. Overall we
have identified eQTL (nominal P < 1.0e-05) at 60 of the
298 heart GWA loci, which represents a highly significant
enrichment (OR = 3.4, P < 2.2e-10, FET) of eQTL for
GWA variants. This is many more than identified in the
donors only in a previous study [56], probably due to a
near doubling in sample size and higher sensitivity of
RNA-seq compared to the gene expression microarray
platform used previously. In the GTEx data, 39 GWA
SNPs were significant eQTL, of which 24 were also identi-
fied in our study. When also considering lowly expressed
genes, the numbers of GWA SNPs with eQTL in our
study increased to 70 (OR = 3.1, P = 2.2e-16, FET) and 45
in GTEx. Overall, these results demonstrate the added
value of an increased sample size for the interpretation of
disease variants. Using a similar strategy, we have also
identified ten GWA SNPs that were trQTL (Additional
file 9).
Inspecting all loci with eQTL in our study or the
GTEx study, we found 19 cases where the GWA SNP
was exclusively an eQTL for the candidate gene nomi-
nated in the original publication, i.e., the lead SNP of the
GWAS was significantly associated with the expression
of the candidate gene. In 17 cases, the GWA SNP was
an eQTL for the candidate gene as well as an additional
gene. These new genes should be considered as possible
alternative candidate genes. In more than half of the
GWA loci with eQTLs (39) the disease SNP was not an
eQTL for the original candidate gene, but for a different
gene in the same locus, which should be considered as
better candidate genes. One example is the SNP
rs2485376, which is associated with the duration of the
QTc interval on the electrocardiogram (ECG)—a param-
eter of cardiac repolarisation [57]. In the original study,
GBF1 was identified as a candidate gene. In our data we
did not find evidence of an association between the SNP
and GBF1, but with PITX3 (P = 4.75E-10). PITX3 is an
interesting candidate, as PITX2, a transcription factor
from the same family, has been implicated in transcrip-
tional regulation of cardiac ion channel genes [58, 59]
and genetic variants close to PITX2 have been associated
with atrial fibrillation [60].
Discussion
In this work we present the largest heart eQTL data
set to date (compare [7, 56]) based on deep RNA-
sequencing of DCM patients and non-diseased donors.
DCM and non-diseased left ventricular tissue showed
marked transcriptome differences. Transcript levels of
both protein-coding and long noncoding genes as well
as their splicing patterns were altered. This affected
many known genes and biological processes involved
in DCM (e.g., TBX20, RBM20) or heart failure (NPPA,
NPPB) and also revealed many novel DCM candidate
genes. Differentially expressed genes such as TBX20
and its target genes constitute a relevant starting point
for mechanistic studies to identify the genes whose
regulation in failing hearts suggests their biological in-
volvement in disease, which may provide novel leads
to study their mechanistic role. Our results provide a
rich source of information about the molecular mecha-
nisms that are altered in DCM, including the differential
expression of non-coding genes and differential splicing,
which previous RNA-seq studies were not able to detect
due to a limited number of samples (two DCM cases
compared to three non-failing controls [61]). Differ-
ences in alternative splicing are particularly interesting
as this process has previously been implicated in the
etiology of DCM [21, 24, 32]. Our results provide fur-
ther support for the role of RBM20 in DCM, as we have
identified differential splicing of RBM20 targets that we
previously identified in rat [24].
The current experimental design has a few limitations
with respect to the differential expression analysis due to
logistical reasons and challenges related to obtaining hu-
man myocardial tissue samples. Ideally the DCM cases
and non-diseased controls would have all been recruited in
the same centers, sequencing should have been performed
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in mixed runs, and both populations should have been
more deeply phenotyped. We have implemented the
following strategies to control the effects of unwanted
confounding: the RNA-seq data were generated in the
same lab, handled via the same procedures, and ana-
lyzed using the same pipeline. The statistical analysis
included all known covariates as applicable and we im-
posed additional thresholds on the fold changes to ob-
tain conservative results. The effectiveness of these
considerations was supported by the observation that
genes and processes were identified that had previously
been associated with DCM. Apart from being a bio-
logical validation, this confirmed that the known and
unknown sources of technical or biological variation
were handled sufficiently. Within the eQTL analyses
we addressed any residual confounding by including la-
tent confounder estimates through the PEER procedure
[62]. The latter approach has been shown to be a ro-
bust and effective method for controlling the influence
of latent confounding factors on detection of eQTLs
based on multi-center RNA-seq data [6, 63]. Neverthe-
less, the fact that samples were collected at different
centers and sequenced over an extended period in a
non-randomized order could still lead to confounding
in the comparison of DCM patients and controls, which
cannot be ruled out completely.
We showed that there is a widespread effect of genetic
variation that affects the regulation of transcription and
splicing, which is congruent with the recently published
insight that transcription and RNA splicing are the pri-
mary links between genetic variation and disease in gen-
eral [12]. We were able to identify significantly more
eQTL in comparison with previously published results
from the GTEx project, which is based on post-mortem
sections [7]. We showed that the effect sizes and direc-
tions were largely concordant between the two studies;
however, many eQTL did not reach genome-wide signifi-
cance levels in the GTEx study, likely due to a slightly
smaller sample size or the effects of post-mortem RNA
degradation. We also detected genetic variants that affect
gene regulation specifically only in DCM patients or in do-
nors, which might be due to an altered trans context in
diseased and non-diseased tissue. Peters et al. [64]
identified cell type- and disease-specific eQTL in im-
mune cells in patients with autoimmune disease, sup-
porting the existence and biological importance of
disease-specific eQTL. We detected ten times as many
QTL affecting the relative abundance of transcript iso-
forms (trQTL) in comparison to the GTEx study and
showed that this is due to increased sample size, se-
quencing depth, and the size of the cis-window. In
agreement with previous studies [6, 7, 42, 43] we
showed that QTL variants are frequently located in cis
regulatory elements, suggesting that these QTL indeed
affect promoters or enhancers for the corresponding
target gene. In line with previous studies [12] we ob-
served that sQTL are located preferentially close to
the exon that they affect. In keeping with results from
[65] we observed enrichment of sQTL in different
chromatin features such as DNAse I sites and pro-
moters. In addition we also observed enrichment in
polycomb-associated regions, which have been shown
to affect splicing [66]. Both observations are compatible
with the idea that chromatin influences co-transcriptional
splicing [67, 68].
We observed allele specific expression for many genes
across DCM and non-diseased donor tissues. Differences
in allelic imbalance between DCM and donors appear to
be small on the individual gene level, yet all differential
allelic imbalanced genes combined are enriched for
DCM-related processes, as well as differential splicing
and miRNA interference. Although we observed ASE in
TTN regardless of disease status, these sites were not
shared between individuals. While truncating variants in
TTN can lead to nonsense-mediated decay [69], there
was no clear pattern emerging from the ASE analysis,
probably due to the difficulty of phasing variants across
the very large TTN transcript. Similar observations
were made in a subset of DCM samples [20]. For the
DCM phenotype, this could indicate that imbalance
shifts towards disease contributing alleles during disease
progression. Although allele-specific expression, allelic
imbalance, and its potential determinants have been
studied genome-wide before [6, 65], to our knowledge
this is the first time that this process has been associated
with a disease.
By analyzing DCM GWA data we showed that eQTL
and sQTL variants are enriched for DCM associations.
However, as we focused solely on DCM GWA data it
remains open whether this enrichment is specific to
DCM or also holds for other diseases and phenotypes.
Building on the enrichment results, we showed that
QTL variants can be used to derive a multilocus risk
score for DCM that outperforms risk scores based on
clinical variables and the GWA hit SNP only. Although
we apply a ten-fold cross validation, this is not a true
replication and is still sensitive to overfitting. In its
current form this risk score therefore has limited use
for clinical applications. It does, however, demonstrate
that QTL variants together encode biological informa-
tion that significantly improves the prediction of the
DCM phenotype. More generally, we found that 20% of
all GWA loci for heart-related phenotypes published to
date alter gene expression levels. Compared to the 13%
identified in the GTEx data set, this increase consti-
tutes a substantial improvement in candidate gene
prioritization, an important bottleneck in GWA study
follow-ups.
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Conclusions
The RNA-seq-based QTL data set of DCM patients and
non-diseased donors generated in this study represents a
powerful resource for the whole field of cardiovascular
genetics. It revealed marked transcriptome differences
between diseased and non-diseased tissue and a wide-
spread effect of genetic variation on the regulation of
transcription and splicing. Moreover it allowed for great
improvements in GWA candidate gene prioritization, fa-
cilitating the elucidation of the mechanisms underlying
the genetic basis of common diseases of the heart.
Methods
Transcriptome profiling in cardiac samples from donors
and patients with DCM
All studies were carried out according to institutional
guidelines, and with appropriate informed consent from
participants or next of kin. Institutional ethics commit-
tees of the centers where the samples were collected
reviewed and approved all protocols.
Left ventricular samples from patients with DCM
Left ventricular tissue samples from patients with end-
stage DCM were retrieved during left ventricular device
implantation or/and cardiac transplantation in the period
between 1993 and 2011. They were snap-frozen and
stored in liquid nitrogen in a tissue bank at the Royal
Brompton and Harefield Hospitals NHS Foundation
Trust. The set of 128 DCM cases originally considered for
this study consisted of end-stage non-ischaemic DCM pa-
tients for whom good quality RNA from left ventricular
tissue was available for RNA-sequencing analysis. Out of
all these included cases, less than 10% report a family his-
tory. The diagnosis of non-ischaemic DCM was confirmed
from medical records, but additional clinical data were not
available. After genotype quality control (see below and
Additional file 1: Table S1) 97 samples were used for data
analysis.
Left ventricular samples from donor hearts
Left ventricular samples were obtained from unrelated
organ donors whose hearts were explanted to obtain
pulmonary and aortic valves for transplant or valve re-
placement surgery or explanted for transplantation but
not used due to logistical reasons. The 108 samples
studied here represent a subset of the 129 samples de-
scribed previously [56]. The selection was based on the
quality of RNA for RNA-seq.
For both cohorts, RNA was extracted from frozen left
ventricle with Trizol (Life Technologies) by following the
manufacturer’s protocol and subsequently the RNA was
quantified using UV spectrophotometry. RNA quality was
assessed with the Agilent 2100 Bioanalyser and RNA 6000
reagents. Non-stranded, poly(A)-selected RNA libraries
were prepared for sequencing using 4 μg of total RNA
as input for the TruSeq RNA Sample Preparation Kit
(Illumina).We then generated 2 × 100-bp reads of barcoded
cDNA fragments of poly(A) + RNA on a HiSeq 2000 (Illu-
mina) using paired-end chemistry. Six samples were pooled
and loaded on three lanes to avoid batch effects and obtain
sufficient coverage for splicing analyses.
Processing of RNA-seq data
The paired-end RNA-seq reads were aligned against the
human genome assembly GRCh37 using TopHat version
1.4.1 with option -r 0. This specifies the mate inner dis-
tance, which is expected to be zero, since we have 200 bp
fragment size and 100-bp reads. In addition we specified
option -M that removes multimapping reads before align-
ing to the transcriptome. The remaining options were set
to their default values. We have supplied transcript anno-
tations from Ensembl version 66, which specifies known
splice junctions and exon boundaries. In addition we also
enabled TopHat’s coverage-based search for novel exons
and splice junctions.
Quantification of the transcriptome
To quantify transcriptome features we have used the
Gencode annotation version 19 and augmented it with
annotation of the MHRT lncRNA locus [26] and a cus-
tom TTN annotation [20]. For gene level quantification
we used htseq-count version 0.5.3p3 and the ‘intersec-
tion-nonempty’ mode that is suited to quantify overlap-
ping transcripts on different strands. Transcript levels
were estimated as fragments per kilobase per million se-
quenced (FKPM) using cufflinks (version 2.2.1) [70] with
the same gene models as above. Exon coverage was
determined using intersectBed from bedtools version
2.15.0. The ‘percent spliced in’ index (PSI) [34] was
computed using scripts from [35] on non-overlapping
exonic parts derived from the Gencode annotation ver-
sion 19 using the script dexseq_prepare_annotation.py
from the DEXSeq R package [2, 9] version 1.8.0.
Heart tissue is mainly composed of cardiomyocytes
and fibroblast cells. In order to avoid confounding by
cell type heterogeneity in the heart tissue samples we
have defined a fibroblast gene expression signature. We
analysed RNA-seq data from cultured rat cardiomyocytes
and heart fibroblasts in order to identify fibroblast-specific
marker genes. Rat cardiomyocytes and fibroblasts were
isolated from hearts of neonatal SD rats as previously
described with minor modifications [2, 3, 7, 13]. Briefly,
1–2-day-old rats were euthanized and their hearts were
excised. Ventricular tissue was minced and incubated
in 0.1% trypsin (Sigma) in HBSS (Biochrom) overnight
at 4 °C. Five or six digestions for 4 min each were per-
formed with 10 ml of 0.1% collagenase (Worthington)
in HBSS. Cells were pooled, collected by centrifugation
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at 1100 rpm, and resuspended in DMEM supplemented
with 10% FCS. To selectively enrich for cardiomyo-
cytes, cells were preplated for 1 h in a T75 flask during
which period cardiofibroblasts attached readily to the
bottom of the flask. The supernatant was then seeded
in 15 cm dishes (~1 × 107 cells/dish) and cardiomyo-
cytes were cultured for 3 days in DMEM supplemented
with 10% FCS. Fibroblasts were cultured for two pas-
sages in 5 days to increase cell purity by overgrowing
non-proliferating myocytes. RNA-sequencing was per-
formed using the same procedures as for the human
samples. Reads were processed as the human data using
the rat reference genome assembly rn4 and Ensembl
version 66. Differentially expressed genes were identi-
fied using DESeq [71]. We selected genes with high ex-
pression levels in fibroblasts, at least tenfold higher
expression in fibroblasts compared to cardiomyocytes,
and FDR <0.05. From this list, we selected genes that
had human homologs. Using this gene list we com-
puted a fibroblast score for each human sample by
summing up the scaled and log10 transformed expres-
sion levels. This fibroblast score was subsequently used
for adjusting expression levels in eQTL and differential
expression analyses.
Genotyping
DCM patients
DNA isolated from peripheral blood samples was used
for genotyping on the Affymetrix GW6 platform at the
Max Delbrück Center in Berlin according to the manu-
facturer’s protocol. Genotype calls for 906,600 SNPs
were obtained from the Affymetrix genotyping console
software version 4.1.4.840 using the birdseed2 algorithm
with default settings. Prior to imputation, quality control
was performed using GenABEL. We checked for sex
mismatches and removed related individuals and individ-
uals with admixed or non-european ancestry (Additional
file 1: Table S1). After quality control (QC) we retained 97
DCM patients for the analysis.
Non-diseased donors
Genotyping and QC of genotypic data and post-QC
processing of the left ventricular samples obtained from
donors has been described in detail previously [56].
Genome-wide SNP genotyping was performed using
Illumina HumanOmniExpress Beadchips interrogating
733,202 genetic markers. QC was carried out in the
GenABEL package in the statistical programming lan-
guage R using default settings. Only the data of the 108
samples for which RNA-seq data were generated were
used in the present study, all of which passed QC and
were part of the original 129 samples used in the original
study [56].
Using data of both populations we checked for popula-
tion structure and computed the first three principal
components for inclusion in our models as covariates.
As independent quality control for both DCM patients
and donors, we obtained SNP calls from RNA-seq data
for known SNP positions in exons based on the 1000
Genomes data set phase 1 version 3. For this analysis we
ran TopHat with very stringent read mapping criteria to
avoid artifacts from misaligned reads. We have then se-
lected all SNP positions for which we were able to ob-
tain high confidence genotype calls (per sample, for each
genotype call, median PHRED score >30, covered by at
least 30 reads, and reference and alternative allele freq in
{0; 0.5; 1} ± 0.25). We used genotypes at 2043 positions
for which data were available from both platforms and
RNA-seq to compare the accuracy (fraction of correct
genotype calls) of the two platforms (Additional file 1:
Table S7). To rule out potential effects of allele specific
expression, we computed accuracy also for individuals
with heterozygous array genotypes only. In addition, we
computed the non-reference accuracy (fraction of cor-
rect minor allele genotype calls).
Genotype imputation
Since the genotypic data in DCM patients and donors
was obtained on different genotyping arrays, which have
an overlap of around only 200,000 SNPs, we used geno-
type imputation to increase the resolution of our genetic
map. The cases were typed on the Affymetrix GW6
array with 906,600 SNPs, while controls were typed on
the Illumina HumanOmniExpress with 733,202 SNPs.
Both genotype data sets were first filtered according to
the following quality criteria. In each data set, we re-
quired SNPs with minor allele frequency (MAF) greater
than 5% to have a call rate of at least 95% and SNPs with
lower MAF to have a call rate of 99%. Moreover the test
for Hardy–Weinberg equilibrium had to be P > 0.0001.
We selected the set of 195,386 SNPs that were typed on
both platforms and passed the quality criteria as the in-
put for the genotype imputation.
The reference haplotypes were obtained from the 1000
Genomes data set phase 1 version 3 that comprises ref-
erence haplotypes for 1092 individuals. We applied sha-
peit v1 for the prephasing of the genotypes. We used
impute v2 for the actual genotype imputation.
We assessed the quality of the imputed genotype calls
using two data sets. The first data set was based on the
genotype calls from the RNA-seq described in the section
genotyping. The second data set consisted of all genotypes
from the SNP array that were not used for the imputation
because they were specific to one of the two arrays. Imput-
ation quality was measured as overall genotype accuracy
(fraction of correct genotype calls), non-reference accur-
acy (fraction of correct minor allele genotype calls), and
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imputation efficacy (fraction of individuals with genotype
confidence P > 0.95). Additional file 1: Figure S3 shows the
imputation quality based on the RNA-seq data. Overall,
we achieved a good efficacy (Additional file 1: Figure S3a)
and also a good accuracy (Additional file 1: Figure S3b).
The non-reference accuracy, however, shows a bimodal
distribution with very high values, but very low values in
some instances. This is expected to occur for low MAF
variants when all individuals are assigned the major allele.
Indeed Additional file 1: Figure S3d shows that the very
low non-reference accuracy values occur at low MAF.
Therefore, to achieve good non-reference accuracy, we
use imputed variants with MAF >0.1 only. Similar results
were obtained using the SNP array-based evaluation (data
not shown).
In order to avoid artifacts in QTL analyses caused by
rare genotypes that coincide with outliers in the expres-
sion data, we substituted homozygous minor alleles that
occurred less than three times by the heterozygous
genotype.
Differential expression
Gene expression counts were normalized using a
quantile-based scaling method [72]. Differential gene ex-
pression was determined from the normalized gene ex-
pression count matrix as follows. The normalized counts
were log transformed and adjusted for the clinical covar-
iates using a linear model. For each gene we computed
residuals from the linear model and added the mean
expression level to preserve the information about the
absolute expression values. Differential expression be-
tween DCM cases and donors was assessed using the
Wilcoxon–Mann–Whitney test. In addition we required
large expression differences (absolute value of the log fold
change greater than log(1.2)) to avoid spurious findings.
Differential exon usage
PSI values were calculated for 245,309 counting bins.
Only those counting bins with 0 < PSI < 1 for all samples
were considered for the analysis; i.e., counting bins that
are excluded or included in all samples are not of inter-
est. We tested for differential exon usage between the
DCM cases and the donors using the two nested linear
models:
Full : PSI e DCM þ fibroblast score þ age
þ RIN score þ sex
Reduced : PSI e fibroblast score þ age
þ RIN score þ sex
and the likelihood ratio test statistic. To focus on bio-
logically relevant hits, we used a conservative cutoff for
the estimated effect size of 0.1 corresponding to a 10%
difference of PSI values.
Similar approaches based on linear regression of PSI
values have been used for the analysis of sQTL [41]. To
assess the expected sensitivity and false discovery rate of
this approach, we performed a simulation study. For
each sample we obtained the total read counts for each
exon. We removed all exons that had zero counts in
more than 10% of the samples. We fitted a negative bi-
nomial distribution to these counts excluding counts lar-
ger than the 90th percentile. Then we simulated total
read counts for all exons from this distribution. In the
next step we simulated the actual inclusion rates (PSI)
for all exons from a uniform distribution. Then we se-
lected 10% of all exons to be differentially used and
modified the actual PSI values by 10% in the samples of
the case group. Finally, we drew the number of inclusion
reads per exon in that sample from a binomial distribu-
tion with the total reads of the exon as size parameter
and the actual PSI of the sample as success probability
and computed the simulated PSI values as inclusion
reads over total reads. We applied the linear regression
model (without the covariates) to the simulated PSI
values and predicted the differential exons using the cri-
teria defined above. The predictions were compared to the
simulated differential exons to compute the sensitivity
(TP/(FN + TP)) and false discovery rate (FP/(FP + TP)).
The simulation was repeated 100 times. Additional file 1:
Figure S10 shows that the false discovery rate is very low
(<1%) and the sensitivity is about 22%, indicating a conser-
vative behavior of the method.
eQTL mapping
We used all 205 samples from DCM patients and donors
for the eQTL analysis. To associate gene expression
values with genotypes we applied the same procedure
that was used in the GTEx study [7]. Briefly, we trans-
formed read counts to RPKM values (reads per kilobase
of transcript per million mapped reads) and selected all
genes that had RPKM >0 in at least 50% of all samples.
We applied quantile normalization across all genes to
obtain comparable gene expression distributions be-
tween samples. Subsequently we quantile normalized the
expression values of each gene across samples to a
standard normal distribution to minimise the effect of
outliers. Ties in the ranking were resolved randomly.
We used the PEER method [62] to correct for hidden
confounding factors in the expression data. Similar to
[6] we evaluated the impact of using different combina-
tions of covariates on the detection rate of cis eQTL. We
compared the number of genes with cis-eQTL (P < 1e-6)
using no covariates, measured covariates (sex, age, fibro-
blast score, RIN score, center), the first three principal
components of the genotype data, measured and genetic
covariates, as well as 5 to 25 PEER factors (Additional
file 1: Figure S11). Note that the DCM status is implicitly
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adjusted for by the center variable, as all DCM cases were
recruited in London. For the final eQTL analysis we used
25 PEER factors and the measured covariates listed above.
eQTL were identified using MatrixEQTL [73] to test all
cis SNPs within a distance of 1 Mb of a gene. In Table 2
and in the comparison with the GTEx study we used
nominal P < 1e-5 as significance threshold, which corre-
sponds to a Benjamini–Hochberg adjusted FDR of 0.1%.
DCM/donor-specific eQTL
DCM- or donor-specific eQTL were identified using a
two-step approach. First we performed separate eQTL
analyses in DCM patients and in donors using the same
method as described above. To avoid imputation arti-
facts we only considered genotypes that were measured
on both platforms. In addition we focused this analysis
on transcripts with Refseq models only. We selected
all SNP–gene pairs for which an eQTL was detected
(FDR <0.05) only in one of the two analyses as candidate-
specific eQTL. In a second step we performed an analysis
using nested linear models to rule out that the eQTL was
not detected due to power issues. We compared a full
model that includes separate slopes and intercepts for
each group, with a reduced model that only contains one
common slope for both groups and intercepts for both
groups. Log transformed normalized gene expression data
adjusted for all available covariates yij of gene i in sample j
was modeled as a linear function of genotype dosage xkj of
SNP k and a group indicator variable gj. Specifically the
two models were:
Full : yij ¼ gj β0 þ β1xij
  þ 1 ‐ gj  β2 þ β3xij  þ εij
Reduced : yij ¼ gj β0 þ β1xij þ 1 ‐ gj
 
β2 þ εij
with εij being the iid normal error term. Models were
compared using the likelihood ratio test as in regular
ANOVA. DCM- or donor-specific eQTL were identified
using FDR <0.05. In addition we required that zero was
in the 95% confidence interval for the estimates of β1 or
β3 to make sure that only one of the two slopes is sig-
nificantly different from zero.
We applied the Armitage trend test (implemented in
GenABEL [74]) for differences in allele frequencies to
assess if DCM- or donor-specific eQTL were due to sys-
tematic differences in allele frequencies between the two
groups.
sQTL mapping
For the sQTL analysis we used exon expression levels of
exon counting bins defined as in [33] using all tran-
scripts from GENCODE v19 that also had a Refseq
model.
We used an adaptation of the DEXSeq model [33] for
sQTL analysis. The original DEXSeq model was designed
for rather small data sets, so it was too slow for analyzing
large numbers of SNPs for each exon and too sensitive for
large sample sizes, detecting very small effects that are
likely false positives. To reduce runtime, we used a regular
linear model with Gaussian error terms instead of a gener-
alized linear model for count data. We therefore quantile-
normalized exon expression levels across all exons within
each sample such that they follow a standard normal
distribution. We encoded SNP genotypes as factors by
rounding the imputed genotype dosages. The normal-
ized exon expression levels yijl of exon l in gene i and
sample j is modeled by two nested models as:
Full : yijl ¼ β0 þ βGij þ βEil þ βSik þ βESilk δll’ þ εij
Reduced : yijl ¼ β0 þ βGij þ βEil þ βSik þ εij
where β0 is an intercept, β
G
i can be thought of gene ex-
pression level in sample j, βEil can be thought of as the
average difference of exon l to the gene expression level,
βSik represents the contribution of the genotype of SNP
k, βESilk δll’ is an interaction term representing the differ-
ence of the exon expression levels between genotypes at
SNP k for exon l′ and epsijl is the iid error term, follow-
ing a normal distribution. For each exon l′ and each
SNP k in a window of ±1 Mb of the gene, we computed
the likelihood ratio test for the comparison of the full
model and the reduced model. The full model is including
the interaction term βESilk that is multiplied by an indicator
variable δll’ , which is one if l = l′ and zero otherwise. To
evaluate the statistical significance of the likelihood ratio
statistic we used the F-distribution with the appropriate de-
grees of freedom depending on the number of exons per
gene and the number of observed genotypes. We tested
only counting bins that were located within exons that were
annotated as alternatively spliced by Ensembl.
To rule out spurious cis sQTL associations that might
arise if the genotypes of sQTL SNPs were correlated
with expression of the DCM-related trans-acting splicing
factor RBM20, we checked the correlation between
RBM20 expression and all cis sQTL SNPs (potential
trans eQTL for RBM20). We report the 1 – π0 estimate
[37] as the upper limit of the percentage of SNPs that
might be false cis sQTL because of confounding by
RBM20 expression.
Transcript ratio QTL mapping
We used isoform quantifications based on cufflinks for
the transcript ratio QTL mapping. As previously de-
scribed, we selected only transcripts with FPKM >0.01
and only genes with at least two transcript isoforms
expressed [7]. To make the results comparable with the
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exon-based sQTL analysis we tested all SNPs in the range
of 500 kb from the gene for association. We used sQTLee-
ker to test association between SNPs and transcript ratios
[41]. This method is based on multivariate analysis of vari-
ance and tests how well the genotype classes can explain
the variation of the samples on the simplex defined by the
relative transcript isoform expression levels. Significance
was determined by permutations and subsequent control
of the false discovery rate (FDR <0.05).
Moreover, we analyzed the effect of the total read
coverage, sample size, size of the cis window, and covariate
adjustment on the detection rate of trQTL. Our main goal
was to obtain numbers that are comparable to the GTEx
left ventricle data set, which comprises 83 samples assum-
ing a read coverage of 80 million, which is close to the me-
dian of 82.1 million of all GTEx samples [7]. Here we used
numbers from GTEx analysis version 4, as these results
are only reported in the paper and not on the website. To
reduce the computational burden of transcript isoform
quantification and sQTL seeker analysis we restricted our-
selves to chromosome 20. We sampled 1.7 million reads
from chromosome 20, assuming that the number of
aligned reads is distributed among chromosomes accord-
ing to their lengths (chromosome 20, 63,025,520; chrom-
somes 1–22 and X, 3,036,303,846). The 83 samples were
randomly selected from the group of donors to remove
possible influence of the disease state. In addition we re-
stricted the radius for cis SNPs to a maximum of 5 kb. We
also adjusted transcript isoform expression levels for the
measured covariates fibroblast score, age, RIN score, sex,
and contributing clinical center. We first computed mean
transcript expression levels and then added an offset of 1
and log transformed the isoform expression levels. Using
these values we performed linear regression against the
covariates and obtained the residuals from the model. Fi-
nally we reversed the log transformation, subtracted the
offset, and added the means to obtain adjusted isoform ex-
pression levels. All negative values were set to zero.
SNP level functional analysis of QTL
To determine whether QTL SNPs preferentially occur in
certain functional elements, we have annotated all SNPs
that were tested for eQTL and sQTL with features based
on gene models from GENCODE v19 and cis regulatory
elements that were determined based on DNA sequence
and chromatin state annotations [45] for the left ven-
tricle of the heart obtained from the Roadmap Epige-
nomics project [44]. To do so, we built a simple logistic
regression model:
log
Pi
1−Pi
 
¼ β0 þ
X
j∈P
βjxij
to predict which SNP is ‘causal’ for a target from its
functional annotation. We considered each pair of SNP
and target, i.e., exon for sQTL and gene for eQTL ana-
lysis, as a data point. Each data point i is a tuple (yi, xi),
where x is a binary vector (xi1,.., xip) indicating whether
the SNP–target pair is annotated with feature j, and yi
indicating whether the SNP is the most significantly as-
sociated SNP for the target. This simple model assumes
that the best SNP is also the ‘causal’ SNP for each target.
Since other significantly associated SNPs might also be
causal and thus functionally relevant, or the causal SNP
might not be the most significantly associated SNP, these
mislabeled data points might dilute the enrichment results
when annotated as ‘not causal’. Therefore, we removed all
data points where the SNP was also significantly associ-
ated with the target but not the top hit. The distance
between SNP and target is an important predictor for
QTL [42], so we grouped the distances into five bins of
size 10 kb, starting from 1 bp, and used these features
for sQTL and eQTL analysis. For both QTL analyses
we used chromatin state annotations from the 25 state
chromHMM segmentation from roadmap. In particular,
we used the states 1) heterochromatin; 2) TSS; 3) bi-
valent promoter; 4) promoter; 5) DNAse; 6) polycomb;
7) weakly transcribed. Additionally, for eQTL analysis,
we annotated whether the SNP was in the 8) promoter
region of the target gene; 9) in an exon of the target
gene; or 10) in an intron of the target gene. And specif-
ically for sQTL analysis, we annotated 11) whether the
SNP was located directly within the target exon; 12)
whether the SNP was located in the neighboring intron
upstream or 13) downstream of the target exon; 14)
whether it was located in the neighboring intron up-
stream or 15) downstream; 16) exonic splice enhancers
(ESE) by matching hexamer sequences defined by [46] to
transcript sequences. We estimated the model parameters
as well as their standard errors, and tested each of the hy-
potheses βj = 0, while controlling for the other variables,
using the likelihood ratio test as implemented in the glm
function of R using the binomial family and logistic link
function [75].
Association of QTL with DCM
To assess the association between regulatory variants
and DCM disease risk we analyzed the results of two
genome-wide association studies for DCM from a Ger-
man [51] and a French [52] population. Enrichment for
DCM GWAs was assessed using an approach that was
initially developed to analyse gene sets [54]. We tested
whether the distribution of GWA P values for QTL vari-
ants is different from the distribution for tested variants
without QTL. Since these studies and our own study
were carried out on different genotyping platforms, we
considered blocks of high linkage disequilibrium (LD)
in the CEU reference population that were tagged by
SNPs in our study and the DCM GWA as basic units
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of analysis. LD blocks were defined using SNAP [53]
with Rsq >0.6. Each LD block was classified as QTL
when it contained at least one SNP with a QTL, and the
smallest DCM GWA P value of all SNPs within the LD
block was considered. The significance of the difference of
P value distributions was assessed using a one-sided
Wilcoxon–Mann–Whitney test with the alternative hy-
pothesis that P values of LD blocks with QTL are smaller.
To assess whether our approach was sensitive towards
outliers that would be selected in the approach consider-
ing the minimal P values, we also repeated the analysis
choosing the second smallest P value for each LD block,
leading to similar results (data not shown).
DCM risk score
We estimated and evaluated different multilocus genetic
risk models trained from varying sets of input variables.
The original DCM GWA [51] genotype data of 292,367
SNPs for 909 DCM cases and 2120 control was gener-
ously provided by the authors. Our method is based on
feature selection by regularized logistic regression (LASSO)
as implemented in the glmnet R package [76]. We prepared
sets of candidate variables for selection into the risk
model. The following SNP sets were considered: 11,771
SNPs with eQTL (P < 10e-5), 9134 SNPs with sQTL
(FDR <0.05), one GWA SNP (rs9262636), and the empty
set. Furthermore we considered combinations of eQTL +
GWA, sQTL +GWA, eQTL + sQTL +GWA. All sets
were extended to include the covariates sex and age. To
evaluate the risk model we performed tenfold cross-
validation. We used the area under the receiver operator
characteristics (ROC) curve as performance measure. In
each fold we reserved 10% of the data for testing and used
the remaining 90% for training of the model. The lambda
parameter, which indicates the weight of the L1 penalty in
the logistic regression model, was determined in a second
nested cross-validation on the training data. We used the
largest lambda, which was within one standard error of
the maximal training AUC as recommended [77] to obtain
parsimonious models.
Analysis of heart GWA SNPs
To assess the value of our eQTL and sQTL results for
nomination of candidate genes for mediating the effect
at loci identified in GWA of heart-related traits, we ob-
tained published GWA results from the GWAS catalog
(accessed 11.12.2015). We selected all traits that were
annotated as heart disease (EFO_0003777) or cardiovas-
cular measurement (EFO_0004298) in the experimental
factor ontology. We removed cardiovascular measure-
ments that were not directly related with the heart. For
the eQTL we intersected the GWA loci with eQTL data
of both our own study and the GTEx study. For each of
the studies, we used proxies (LD >0.8) for GWA SNPs
that were not in the dataset. To avoid double counting
because of LD, we selected only the best proxy SNPs for
each pair of GWA SNP and potential cis eQTL gene. LD
information was obtained from the SNAP database [53].
sQTL were analyzed in the same way, but using only
sQTL data from our study. For eQTL-GWA analysis we
used genes with RPKM >1 in >5% of the samples, to se-
lect candidates that are amenable to biological follow-up
analysis. Enrichment of heart GWA SNPs among eQTL
was assessed as follows. We considered all SNPs tested
for cis eQTL for the selected genes as the basic popula-
tion. Then we classified each SNP as eQTL (P < 1e-5) or
non-eQTL and GWA (GWA SNP or its best) or non-
GWA. Finally, we applied Fisher’s exact test to determine
the significance.
Allele-specific expression analysis
To characterize the allele-specific expression (ASE) in
each individual, we performed an allelic imbalance ana-
lysis analogous to previously published work [6, 78] and
outlined in detail in a best practices article [79]. Briefly,
the analysis was based on binomial testing of each allelic
ratio of heterozygous sites (as determined from the Illu-
mina microarray genotyping data) within each individ-
ual. Sites prone to allelic mapping bias were excluded: 1)
sites in regions with low mappability according to the
mappability track of UCSC (50 bp mappability <1 implies
that the flanking region of the site is non-unique in the
genome); 2) sites for which simulated overlapping 50-bp
reads show >5% difference in the mapping of reads that
carry the reference or non-reference allele (simulation
results kindly provided by the GEUVADIS consortium
[6, 78]). We adhered to strict quality settings in calling
genotypes from the raw RNA-seq reads, requiring a
PHRED base quality score larger than 30 and a coverage
of at least 30 reads for each site. Additionally, only sites
where both alleles are observed in the RNA-sequencing
data were considered to ensure that the observed genotype
for the site is truly heterozygous. To correct for any
remaining genome-wide mapping bias in addition to GC
bias, average reference allele ratios were calculated for
each individual. Using these expected ratios, a binomial
test of the reference and non-reference allele counts was
performed. To account for large differences in expression,
reflected in large differences in total allele counts, driving
the results, all sites were resampled to the mean total allele
count of all heterozygous sites. P values were subsequently
corrected for multiple testing using the q-value method
[37] from the qvalue package in R.
To summarize results afterwards, for all sites (that are
heterozygous in at least one individual) we calculated
how many individuals are heterozygous and how many
show allelic imbalance, both in the total set (n = 205) as
well as in the donors (n = 108) and DCM (n = 97) samples
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separately. Allelic imbalance differences between DCM
and donors were calculated in two ways. Difference in
number of imbalanced individuals was calculated using a
Fisher’s exact test (FET; ‘FET P value’ abbreviated as ‘FET
P’). The difference in imbalanced allele was determined
using a test of proportions. In assessing differentially
imbalanced sites between DCM cases and non-diseased
donors we applied LD pruning on the set of imbalanced
variants using results from SNAP (1000 Genomes;
R2 > 0.8) to keep only independent variants.
Functional enrichment of imbalanced sites was per-
formed using the NEXUS variant annotation tool [80].
Additionally, overlap with known truncating variants
and known imprinted genes (source http://www.geneim-
print.com/site/genes-by-species.Homo+sapiens; accessed
14-01-2016) was determined. To assess co-occurrence of
miRNA binding sites, only conserved predicted sites
from TargetScan 7.0 were used (accessed 30-03-2016).
Overrepresentation of eQTL and differential splicing
identified in the present study was determined using
odds ratios with confidence intervals. Functional enrich-
ment of associated genes was performed using the topGO
package in R, using the parent-child algorithm [81] with a
minimum node size of 5.
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